Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesOphthalmology/OptometryBCBS MA VEGF/complement inhibitors Coverage Update…
    Ask Trek AI about this page
    ModifiedBlue Cross Blue Shield - MassachusettsPolicy 092

    VEGF inhibitors and complement inhibitors for macular degeneration and diabetic eye disease

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Massachusetts Policy 092 alerts

    Get alerted when Policy 092 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical coverage and prior authorization requirements for VEGF inhibitors and complement inhibitors used to treat macular degeneration, diabetic eye disease, and related retinal conditions for BCBSMA commercial members.

    Policy Summary
    PayerBlue Cross Blue Shield - Massachusetts
    PolicyVEGF inhibitors and complement inhibitors for macular degeneration and diabetic eye disease
    Policy CodePolicy 092
    Change TypeUpdated Eylea HDclarified bevacizumab PA statusadministrative removals from Cotivity
    Effective Date
    Next Review Date
    Key ActionSubmit prior authorization using the Massachusetts Standard Form for Medication Prior Authorization Requests (eForm or Form #434).
    SourceLink
    POLICY UPDATE CHANGES

    Updated Eylea HD with expanded FDA indications.

    Removed Eylea and Pavlu from Cotivity program.

    Clarified no prior authorization required for any bevacizumab with ophthalmic administration.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Most agentsdrugs requiring PA
    No PA requiredbevacizumab PA
    Commercialmember types
    1eForm link
    1faxable form #
    17references listed

    Coverage Criteria

    MEDICALLY NECESSARY criteria for VEGF inhibitors

    Covered when ALL of the following are met:

    General requirements for listed VEGF inhibitors (Bevacizumab-excepted agents)

    • Permitted diagnoses for this group: a. Neovascular (Wet) Age-Related Macular Degeneration (AMD); b. Macular Edema Following Retinal Vein Occlusion (RVO); c. Diabetic Macular Edema (DME); d. Diabetic Retinopathy (DR); e. Myopic Choroidal Neovascularization (mCNV).

      from chunk 9

    Eylea HD specific criteria: 1. Age 18 years and older; AND 2. Treatment failure or contraindication to Avastin (bevacizumab); AND 3. Confirmed diagnosis of one of: Neovascular (Wet) AMD; Diabetic Macular Edema (DME); Diabetic Retinopathy (DR); Macular Edema Following RVO.

    from chunk 10

    Eylea specific criteria: 1. Age 18 years and older; AND 2. Treatment failure or contraindication to Avastin (bevacizumab); AND 3. Confirmed diagnosis of one of: Neovascular (Wet) AMD; Macular Edema Following RVO; Diabetic Macular Edema (DME); Diabetic Retinopathy (DR); Retinopathy of Prematurity (ROP).

    from chunk 11

    Pavblu specific criteria: 1. Age 18 years and older; AND 2. Treatment failure or contraindication to Avastin (bevacizumab); AND 3. Confirmed diagnosis of one of: Neovascular (Wet) AMD; Macular Edema Following RVO; Diabetic Macular Edema (DME); Diabetic Retinopathy (DR); Retinopathy of Prematurity (ROP).

    from chunk 12

    MEDICALLY NECESSARY criteria for complement inhibitors (GA)

    Covered when ALL of the following are met:

    Izervay or Syfovre for Geographic Atrophy: 1. Age 18 years and older; AND 2. Confirmed diagnosis of Geographic Atrophy (GA); AND 3. Absence of Choroidal Neovascularization (CNV) in both eyes; AND 4. Secondary to Age-Related Macular Degeneration (AMD).

    from chunk 14

    Complement inhibitors for Geographic Atrophy are covered only when specific anatomic and etiologic conditions are met. Specifically, coverage of Izervay (avacincaptad pegol) or Syfovre (pegcetacoplan) requires a confirmed diagnosis of Geographic Atrophy (GA) in a patient aged 18 years or older, and there must be an absence of choroidal neovascularization (CNV) in both eyes. Additionally, the GA must be secondary to age-related macular degeneration (AMD). Presence of CNV or GA from a non‑AMD cause therefore excludes coverage under these criteria.

    This section does not present an explicit list of agents designated as not medically necessary. The policy summary and tables list covered agents and their formulary or prior‑authorization status, but no discrete 'not medically necessary' statements for specific intravitreal agents appear in the cited portions of the document.

    Coding and Billing Codes

    Covered agents and PA statusmixed
    Bevacizumab (all brands)Covered under Medical Benefit Only; No Prior Authorization required
    Beovu (brolucizumab)Covered under Medical Benefit Only; Prior Authorization required
    Byooviz (ranibizumab nuna)Covered under Medical Benefit Only; Prior Authorization required
    Cimerli (ranibizumab eqrn)Covered under Medical Benefit Only; Prior Authorization required
    Eylea (aflibercept)Covered under Medical Benefit Only; Prior Authorization required
    Eylea HDCovered under Medical Benefit Only; Prior Authorization required
    Lucentis (ranibizumab)Covered under Medical Benefit Only; Prior Authorization required
    Pavblu (aflibercept)Covered under Medical Benefit Only; Prior Authorization required
    Susvimo (ranibizumab)Covered under Medical Benefit Only; Prior Authorization required
    Vabysmo (faricimab)Covered under Medical Benefit Only; Prior Authorization required
    Complement inhibitors for Geographic Atrophymixed
    Izervay (avacincaptad pegol)Covered under Medical Benefit Only; Prior Authorization required
    Syfovre (pegcetacoplan)Covered under Medical Benefit Only; Prior Authorization required

    Provider Actions — Prior Authorization & Documentation

    Prior Authorization

    Prior Authorization Required

    Requests for intravitreal VEGF inhibitors covered under the medical benefit require prior authorization. Failure to obtain prior authorization when required may result in claim denial.

    • Affected agents include Beovu, Byooviz, Cimerli, Eylea, Eylea HD, Lucentis, Pavblu, Susvimo, Vabysmo (all listed as Medical Benefit with PA).
    • Bevacizumab (all brands) is covered under the Medical Benefit and does NOT require prior authorization.
    Documentation Required

    Use Massachusetts Medication Prior Authorization Form

    Use the Massachusetts Standard Form for Medication Prior Authorization Requests to submit PA requests. You may complete the eForm online or print and fax Form #434; failure to submit a completed form (eForm or Form #434) may risk denial of the request.

    • eForm link: https://www.bluecrossma.org/medical-policies/sites/g/files/csphws2091/files/acquiadamassets/023%20E%20Form%20medication%20prior%20auth%20instruction%20prn.pdf

    Background

    Vascular endothelial growth factor (VEGF) inhibitors and complement inhibitors are therapeutic classes used to manage a range of retinal diseases. Anti‑VEGF agents—including ranibizumab, bevacizumab, aflibercept, brolucizumab and related biosimilars—are used to treat neovascular (wet) age‑related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV), among other retinal conditions. Complement inhibitors such as Izervay and Syfovre are indicated for Geographic Atrophy (GA) secondary to AMD and per policy require the absence of choroidal neovascularization in both eyes to meet coverage criteria. Studies cited in the policy also note that repackaged bevacizumab (Avastin) has not been associated with a higher risk of endophthalmitis compared with ranibizumab in large observational and randomized studies, supporting its use as a treatment option.

    Definitions & Safety Notes

    Repackaged Avastin safety — study findings and switching strategies
    Key finding on repackaged bevacizumab (Avastin)Large observational and randomized studies found repackaged bevacizumab was not associated with a higher risk of endophthalmitis compared with ranibizumab (Lucentis)
    Switching strategy outcomesA 2022 NEJM trial reported patients starting on bevacizumab who were switched to aflibercept (Eylea) when necessary had comparable 2‑year outcomes to patients started on aflibercept
    Evidence sourcesFindings summarized from a 2015 comparative study (N≈296,000 Avastin vs N≈87,000 Lucentis) and a 2022 NEJM randomized trial
    Anti‑VEGF and related intravitreal agents — medications referenced
    Ranibizumab (Lucentis and biosimilars)Listed among referenced intravitreal anti‑VEGF agents and package inserts (Lucentis, Byooviz, Cimerli, Susvimo)
    Bevacizumab (Avastin)
    Policy Summary
    PayerBlue Cross Blue Shield - Massachusetts
    PolicyVEGF inhibitors and complement inhibitors for macular degeneration and diabetic eye disease
    Policy CodePolicy 092
    Change TypeUpdated Eylea HDclarified bevacizumab PA statusadministrative removals from Cotivity
    Effective Date
    Next Review Date
    Key ActionSubmit prior authorization using the Massachusetts Standard Form for Medication Prior Authorization Requests (eForm or Form #434).
    SourceLink
    On This Page
    Coverage CriteriaCoding and Billing CodesProvider Actions — Prior Authorization & DocumentationBackgroundDefinitions & Safety Notes
  1. Or print and fax: Massachusetts Standard Form #434
  2. Step Therapy

    Step Therapy Status

    This policy is focused on prior authorization requirements rather than a step therapy pathway. Historical step therapy edits were removed and the policy was updated to a prior authorization policy; check policy history for prior step therapy changes.

    • Policy history: step therapy elements removed and policy converted to PA-focused (see history entries through 2024–2026).
    • For current coverage and PA criteria, follow the Prior Authorization Required guidance above.
    Note

    Step Therapy (Not Specified)

    No explicit step therapy sequencing is required under this policy at present. Providers should document trials of formulary alternatives only when relevant to support medical necessity or exceptions.

    • Although prior versions included step therapy, current requirements do not mandate a specific step sequence.
    • If a provider asserts that formulary alternatives were tried and failed, include name, strength, dates (if available), and specifics of treatment failure in documentation.
    Included as a referenced agent; repackaged bevacizumab is discussed regarding safety and is listed among covered agents
    Aflibercept (Eylea, Eylea HD, Pavblu)Referenced with package inserts for Eylea and Eylea HD and Pavblu cited in the policy references
    Brolucizumab (Beovu)Included in the list of intravitreal anti‑VEGF agents referenced by the policy
    Faricimab (Vabysmo)Referenced in the summary and package insert list as an intravitreal agent
    Complement inhibitors and related ophthalmic agentsAlso lists multiple biosimilars and ophthalmic agents in the references (e.g., Izervay, Syfovre included elsewhere for GA)